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ate dose constraints are applied to the clinical target volume (CTV), 
planning target volume (PTV), contralateral lung, heart, spinal cord, 
esophagus, liver and kidneys. Beam geometry consisted of 8 non-
overlapping coplanar beams (mixed 6/10 MV photons). The PTV was 
prescribed 50 Gy in 25 daily fractions over 5 weeks. Bolus was applied 
over the scar to ensure adequate skin dose. The plan was optimized in 
the partially ﬁlled TC case. A density override was applied to the TC to 
simulate the completely ﬁlled TC (1 g/cm3) and completely empty (0 
g/cm3) cases, assuming identically treated plans (same monitor units). 
The doses to the regions of interest were compared.
Results: Comparing the empty, partially ﬁlled and full TC cases re-
spectively, we ﬁnd: mean CTV dose 53.4. 50.7 and 49.6 Gy, mean PTV 
dose 53.1, 50.4 and 49.4 Gy; mean contralateral lung dose 8.8, 8.4 and 
8.3 Gy; mean heart dose 32.0, 28.4 and 28.5 Gy; max spinal canal dose 
50.0, 48.9 and 47.3 Gy; max esophagus dose 56.5, 54.0 and 54.6 Gy; 
mean liver dose 20.6, 19.8 and 19.9 Gy; mean ipsilateral kidney dose 
6.9, 7.1 and 7.1 Gy. 
Conclusions: Dosimetric differences between partially ﬁlled and full 
TC are modest, usually within 1 Gy, and, thus, not likely to be of major 
clinically relevance. In general, the empty and full TC had slightly 
warmer and cooler doses, respectively, compared to the partially ﬁlled 
TC case but this was not universally true for all organs at risk. The 
empty TC had the largest dosimetric differences, sometimes exceeding 
2 Gy, compared to the other cases and, thus, may warrant further clini-
cal study and caution.
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Background: Bronchoscopic intervention as initial treatment for rela-
tively benign intraluminal lesions has been shown to potentially spare 
lung parenchyma without compromising long-term outcome, relative to 
surgical resection. 
Aim: To evaluate outcome of bronchoscopic treatment for patients 
with lipoma, neuroﬁbroma, hamartoma, chondroma, hemangioma, 
papilloma, granular cell myoblastoma and low-grade mucoepidermoid 
carcinoma involving the tracheobronchial tree.
Methods: Retrospective review of pathology and bronchoscopy data-
bases between 1992 and 2006 was performed to identify patients with 
relatively benign airway tumors referred to our hospital for broncho-
scopic intervention. Initial clinical work-up included high resolution 
computed tomography (HRCT) for tumor location and invasion. All 
patients underwent rigid bronchoscopy for diagnostic and therapeutic 
indications. Endobronchial electrosurgery followed by mechanical 
debulking of the intraluminal tumor. Restaging with bronchoscopy and 
HRCT were carried out 4-6 weeks after bronchoscopic intervention. 
Patients with extraluminal or residual tumor and distal lung atelectasis 
were advised for surgery.
Results: We identiﬁed 44 patients, 15 females with median age 54 
yrs (range 18 -81), who were initially treated bronchoscopically:16 
(chondro)hamartomas, 6 mucoepidermoid carcinomas, 6 granular cell 
myoblastomas, 4 lipomas, 3 papillomas, 3 adenomas, 2 neuroﬁbromas, 
1 hemangioma, 1 lymfangioma, 1 leiomyoma and 1 paraganglioma. 
Thirty-ﬁve patients (80%) were curatively treated by bronchoscopic 
treatment alone (80%). In the remaining nine patients, radical resection 
was performed. Median follow-up until March 2007 was 38 months 
(range: 4-152) and there were no complications observed in patients 
who underwent bronchoscopic treatment. There has been one patient 
with a recurrence of a hamartoma 20 weeks after bronchoscopic inter-
vention; a segmentectomy was performed. 
Conclusion: Bronchoscopic treatment of relatively benign intraluminal 
tumors in the treacheobronchial tree can be initiated and is a safe alter-
native for surgery, which can be performed if bronchoscopic treatment 
initially failed. 
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Background: Evaluate efﬁcacy of diagnostic measures and surgery for 
malignant pleural mesothelioma (MPM) and analyse results of treat-
ment. 
Matherial and Methods: Form 1992-2005 yy. 138 patients (pts) 
underwent treatment for morphologicaly proved malignant pleural 
mesothelioma in Department of Thoracic Surgery and Oncology, 
Institute Oncology Vilnius University. 113 (81.9%) pts were operated, 
25 (18.1%) pts underwent conservative treatment (radiation/chemo-
therapy). Before operation noninvasive diagnostic procedures were 
used: X-ray ﬁlms 138 (100%) pts, X-ray ﬁlms and chest CT 56 (40.5%) 
pts, chest CT 62 (44.9%) pts, chest CT/MRI 10 (7.2%) pts and chest 
ultrasound 10 (7.2%) pts. Invasive diagnostic procedures: VATS - 45 
(32.6%) pts, pleural biopsy 82 (59.4%) pts, diagnostic (mini) thoracot-
omy 11 (7.9%) pts. Stage of the disease: I st. - 17 (12.3%) pts, II st.- 35 
(25.3%) pts, III st. - 60 (43.4%) pts and stage IV - 26 (18.8%) pts. 53 
pts after surgery were treated using radiation/chemotherapy. 
Results: Operation for MPM: pleuropulmonectomy - 68 (60.1%) pts, 
extented pleuropulmonectomy with pericardium and diafragm resection 
- 12 (10.6%), parietal pleurectomy - 12 (10.6%), partial pleurectomy 
with pericardial resection - 11 (9.7%) pts, debulking - 10 (8.8%) pts. 
Morphology found: epitheliod - 48 (35.7%) pts, sarcomatosus - 53 
(38.4%) pts and biphasic - 37 (26.8%) pts. Postoperative complications: 
bronchial ﬁstulas - 6 (5.3%) pts, chylothorax - 7 (6.1%) pts, hemotho-
rax - 11 (9.7%) pts and injury of simpatic ganglion - 2 (1.7%) pts. 4 
(3.5%) pts dead after surgery. Median survival after surgery was 12,0±2 
mo., after conservative treatment - 6,0±2 mo. Reccurence of the disease 
in surgical group ranges from 9.7-17.6% of pts, in conservative group 
no one pts lived three years. 
Conclusions: 1. Surgery for MPM is conﬁdent, radical and sufﬁcient 
method of treatment. 2. Nonradical resections and postoperative 
chemoradiation prolongs disease free survival and overall survival. 3. 
Postoperative complications was in 26 (23% ) pts, 4 (3.5%) pts dead. 4. 
Median survival after surgery was 12,0±2 mo., after conservative treat-
ment - 6,0±2 mo. Reccurence of the disease in surgical group ranges 
from 9.7-17.6% of pts, in concervative group 93%. 
